

Freedom of Information Team  
Room 1.16  
De La Court House  
Queen Alexandra Hospital  
Southwick Hill Road  
Portsmouth  
Hampshire  
PO6 3LY

Tel: 023 9228 6000 Ext 3708

Name:  
Date: 26/06/2020  
Ref: 20-21 046

Dear

**Freedom of Information request**

Thank you for your request for information under the Freedom of Information Act 2000, which was received by our Freedom of Information team on 27/05/2020.

**1. Within your trust how many intra-vitreous injections/implants of each of the following drugs have been used in the four-month period from January to April 2020:**

Drug	Strength	Jan 2020	Feb	Mar	April	Comment
Abicipar pegol	-	-	-	-	-	Not used at PHT
Aflibercept	4mg/0.1mL intravitreal	298	279	228	149	
Bevacizumab	1.25mg in 0.05mL	28	23	28	10	Some patients do require a double dose. Manufactured by our licenced unit.
Brolucizumab	-	-	-	-	-	Not used at PHT
Dexamethasone	700 mcg intravitreal	25	14	13	5	
Fluocinolone	190 mcg intravitreal	1	0	3	0	
Ranibizumab	0.5mg in 0.05mL	274	224	201	143	

**2. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions listed below.**

The Trust is only able to provide information in relation to drug dispensing as we are unable to link the type of drug to diagnosis on our clinical system. The Trust has provided the units that were used for each intra-vitreous injections/implants in the table provided in question 1.

**Wet Age Related Macular Degeneration (wAMD)**

*Abicipar pegol*  
*Aflibercept*  
*Bevacizumab*  
*Brolucizumab*  
*Dexamethasone*  
*Fluocinolone*  
*Ranibizumab*

**Diabetic Macular Oedema (DMO)**

*Abicipar pegol*  
*Aflibercept*  
*Bevacizumab*  
*Brolucizumab*  
*Dexamethasone*  
*Fluocinolone*  
*Ranibizumab*

**Retinal Vein Occlusion - Central (CRVO)**

*Abicipar pegol*  
*Aflibercept*  
*Bevacizumab*  
*Brolucizumab*  
*Dexamethasone*  
*Fluocinolone*  
*Ranibizumab*

**Retinal Vein Occlusion - Branch (BRVO)**

*Abicipar pegol*  
*Aflibercept*  
*Bevacizumab*  
*Brolucizumab*  
*Dexamethasone*  
*Fluocinolone*  
*Ranibizumab*

**Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)**

*Abicipar pegol*  
*Aflibercept*  
*Bevacizumab*  
*Brolucizumab*  
*Dexamethasone*  
*Fluocinolone*  
*Ranibizumab*

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on [Information.Governance@porthosp.nhs.uk](mailto:Information.Governance@porthosp.nhs.uk) or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team